CORONA Remedies Board Approves FY26 Results, Recommends Dividend, Appoints New Auditors
CORONA Remedies Limited reported audited standalone and consolidated financial results for Q4FY26 and FY26. The board recommended a final dividend of ₹10 per share. Key appointments include M/s. Walker Chandiok & Co LLP as Statutory Auditors for five years, and Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for five years.
The financial results, dividend recommendation, and auditor changes are significant corporate actions that can impact investor perception and company governance.
The company reported positive financial results, recommended a dividend, and made key auditor appointments, indicating stability and forward-looking management.
CORONA Remedies Limited announced the outcome of its Board Meeting held on May 11, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the fourth quarter and the year ended March 31, 2026, along with the audit reports. The auditors' reports were unmodified.
The Board recommended a final dividend of ₹10/- (100%) per equity share of face value ₹10/- each, subject to shareholder approval at the ensuing Annual General Meeting (AGM). The record date for this dividend has been fixed as Friday, June 19, 2026, with the payment scheduled on or before August 07, 2026.
In terms of auditor appointments, the Board approved the recommendation to appoint M/s. Walker Chandiok & Co LLP as the Statutory Auditor for a period of five consecutive years, commencing from the conclusion of the 22nd AGM until the conclusion of the 27th AGM (FY 2026-27 to FY 2030-31), pending member approval. M/s. Dhara Patel, a peer-reviewed Company Secretary firm, was recommended for re-appointment as Secretarial Auditor for five consecutive years from FY 2026-27, also subject to member approval.
Furthermore, M/s. Shah & Shah Associates were approved as the Internal Auditor for FY 2026-27, and M/s. Manish B. Analkat was approved for re-appointment as Cost Auditor for FY 2026-27.
The Board also approved the recommendation for the re-appointment of Dr. Kirtikumar Mehta as Non-Executive Director and Chairman for a term of five consecutive financial years effective April 01, 2027, subject to shareholder approval. The company affirmed that Dr. Mehta is not debarred from holding directorship by any SEBI order.
The Board meeting commenced at 2:30 p.m. and concluded at 4:00 p.m. The company also confirmed that a press release on the financial results is enclosed and that the results and audit report will be available on the company's website.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.